Related Experiment Video
Updated: Feb 28, 2026
04:37
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
794
Pharmacogenomics-guided personalized therapy for hypertension: a multicenter randomized trial
Mingzhong Yu1,2,3,4,5, Min Pan1,2,3,4,5, Bangbang Huang1,2,3,4,5
1Department of Geriatrics, the First Affiliated Hospital of Fujian Medical University.
Journal of Hypertension
|February 26, 2026
Summary
Pharmacogenomics-guided personalized medication significantly improved blood pressure control and reduced medication needs in hypertensive patients. This precision medicine approach offers enhanced hypertension management without increasing adverse events.
Area of Science:
- Cardiology
- Pharmacogenomics
- Precision Medicine
Background:
- Uncontrolled hypertension poses a significant healthcare challenge.
- Pharmacogenomics offers potential for personalized hypertension management.
Purpose of the Study:
- To evaluate if pharmacogenomics-guided personalized medication improves blood pressure control and optimizes medication in hypertensive patients compared to standard care.
Main Methods:
- A multicenter, single-blind, randomized controlled trial involving 776 hypertensive outpatients.
- Patients were assigned to either a personalized medication group (guided by 7 pharmacogenetic polymorphisms) or a control group.
- Outcomes assessed included blood pressure control, medication use, and adverse events after 8 weeks of treatment.
Main Results:
- The personalized medication group showed significantly higher blood pressure control rates, especially in female patients.
- Fewer antihypertensive medications were required in the personalized group.
- No significant difference in adverse events was observed between groups; CYP2C9*3 variant linked to uncontrolled blood pressure.
Conclusions:
- Pharmacogenomics-guided personalized medication regimens effectively improve blood pressure control and medication optimization.
- This precision therapy approach enhances hypertension management without increasing safety concerns.
- Pharmacogenomics holds promise for tailoring antihypertensive treatments to individual genetic profiles.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
63
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
01:29Pharmacogenetics and Pharmacogenomics: Overview
74
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
74
01:27Pharmacogenetics of Drug Metabolism: Overview
68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
54
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
790
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
790